Pfizer had a mixed 2017, with its stock gaining just over 10% - lower than the overall stock market as well as the healthcare sector - and its revenues remaining largely flat relative to 2016 levels.
Pfizer had a mixed 2017, with its stock gaining just over 10% - lower than the overall stock market as well as the healthcare sector - and its revenues remaining largely flat relative to 2016 levels.
Share this Article
Recommended